NIH Research Evaluation and Commercialization Hubs (REACH)

The National Institutes of Health (NIH), within the U.S. Department of Health and Human Services, is preparing to release a Notice of Funding Opportunity for the NIH Research Evaluation and Commercialization Hubs (REACH) program. NIH is the primary federal agency responsible for biomedical and public health research in the United States, and this program aligns with its broader mission to translate scientific discoveries into tangible health outcomes. The REACH initiative specifically focuses on accelerating the commercialization of biomedical innovations developed in academic settings, bridging the gap between early-stage research and real-world application. The primary objective of the REACH program is to establish and fund academic entrepreneurship hubs that can identify, evaluate, and advance promising biomedical technologies. These hubs will function as centralized support systems within universities and research institutions, helping investigators move discoveries from the laboratory toward viable commercial products. NIH anticipates funding approximately five such hubs, which will collectively form a consortium designed to enhance collaboration, share best practices, and increase the efficiency of technology development pipelines. Funding under this program is intended to support early-stage product development activities. Allowable uses include feasibility studies, prototype development, and proof-of-concept research. In addition to financial support, the hubs will provide access to multidisciplinary expertise, including regulatory guidance, reimbursement strategy, legal and intellectual property support, business development, and project management. The program also emphasizes training and mentorship, offering researchers hands-on experience in entrepreneurship and commercialization processes. While there is no formal cost-sharing requirement specified, the program highlights the importance of public-private partnerships and encourages the incorporation of non-federal matching funds as a factor contributing to program success. This suggests that while not mandatory, leveraging external funding sources may strengthen an application. The initiative builds upon prior REACH hub models and aligns with legislative authority under the SBIR/STTR Reauthorization Act and subsequent extensions, reinforcing its role in national innovation policy. Eligibility is limited to academic and nonprofit research institutions, including public and private institutions of higher education and nonprofit organizations with or without 501(c)(3) status. However, a key eligibility requirement is that the primary applicant must have prior participation in the NIH Small Business Technology Transfer (STTR) program as a formal partner with a small business. This ensures that applicants have demonstrated experience in collaborative, translational research environments. At the time of this forecast notice, applications are not yet being accepted. The estimated application due date is November 30, 2026, with an anticipated award date of April 30, 2027, and project start date of June 1, 2027. NIH has issued this forecast to allow prospective applicants sufficient time to form partnerships and develop competitive proposals. Submission will likely occur through standard NIH grant mechanisms once the official funding announcement is released. For additional information or inquiries, applicants may contact the NIH SEED Office, which oversees small business education and entrepreneurial development initiatives. The office can be reached via email at nihreach@nih.gov or by phone at 301-827-8595. This early notice phase is critical for institutions to prepare strategically, align resources, and develop collaborations that meet the program’s emphasis on innovation, commercialization, and public health impact.

Focus on building strong public private partnerships and demonstrating commercialization pathways for biomedical technologies